CardioVascular BioTherapeutics Company Description
Far from being a heartbreaker, Cardiovascular BioTherapeutics works to patch 'em up. The development-stage firm is working on a therapeutic regimen to treat patients with coronary artery disease. Its lead product candidates are based on a fibroblast growth factor protein that induces angiogenesis (blood vessel growth). When injected directly into the heart near affected arteries, the protein has been shown to help repair the artery and increase blood flow to the heart. The company hopes to prove that the protein technology will also help stroke victims and diabetes patients, as well as help heal vertebral injuries and assist in bone growth.
View the Comprehensive Company Description for CardioVascular BioTherapeutics
The Company Description provides a historical perspective of CardioVascular BioTherapeutics's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of CardioVascular BioTherapeutics's evolution in the marketplace.
